home / stock / dare / dare quote
Last: | $3.09 |
---|---|
Change Percent: | 7.44% |
Open: | $3.36 |
Close: | $3.09 |
High: | $3.44 |
Low: | $3.05 |
Volume: | 86,738 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.09 | $3.36 | $3.09 | $3.44 | $3.05 | 86,738 | 07-03-2024 |
$3.63 | $3.58 | $3.63 | $3.96 | $3.5515 | 46,953 | 07-02-2024 |
$3.79 | $3.43 | $3.79 | $4.08 | $3.25 | 219,825 | 07-01-2024 |
$4.0332 | $4.812 | $4.0332 | $4.812 | $3.9122 | 1,649,924 | 06-28-2024 |
$0.3685 | $0.3867 | $0.3685 | $0.419 | $0.34 | 3,253,546 | 06-27-2024 |
$0.4313 | $0.4399 | $0.4313 | $0.47 | $0.4301 | 153,102 | 06-26-2024 |
$0.4326 | $0.465 | $0.4326 | $0.4651 | $0.4309 | 117,887 | 06-25-2024 |
$0.443 | $0.439 | $0.443 | $0.48 | $0.439 | 162,231 | 06-24-2024 |
$0.4345 | $0.42 | $0.4345 | $0.44 | $0.42 | 195,688 | 06-21-2024 |
$0.4217 | $0.45 | $0.4217 | $0.45 | $0.4209 | 285,899 | 06-20-2024 |
$0.43 | $0.44 | $0.43 | $0.44 | $0.4245 | 301,726 | 06-19-2024 |
$0.43 | $0.44 | $0.43 | $0.44 | $0.424514 | 301,726 | 06-18-2024 |
$0.4349 | $0.4479 | $0.4349 | $0.4497 | $0.43 | 178,756 | 06-17-2024 |
$0.4498 | $0.44 | $0.4498 | $0.4548 | $0.4211 | 229,619 | 06-14-2024 |
$0.4354 | $0.449 | $0.4354 | $0.4599 | $0.42 | 355,377 | 06-13-2024 |
$0.441 | $0.48 | $0.441 | $0.48 | $0.441 | 182,514 | 06-12-2024 |
$0.4636 | $0.47 | $0.4636 | $0.48 | $0.461 | 136,472 | 06-11-2024 |
$0.4801 | $0.48 | $0.4801 | $0.485 | $0.46 | 247,139 | 06-10-2024 |
$0.52 | $0.4383 | $0.52 | $0.52 | $0.4383 | 810,082 | 06-07-2024 |
$0.4383 | $0.43 | $0.4383 | $0.442899 | $0.41 | 281,969 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...